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Resistant Nosocomial Enterococcal Infections 
Dennis R. Schaberg, MD 
Department of Internal Medicine, Vniversig of Michigan Medical Center 
Ann Arbor, Michigan 
Enterococcus faecalis, formerly clas- 
sified as Streptococcus faecalis, be- 
longs to Lancefield group D and is 
frequently isolated from nosocomial 
infections. Of the nosocomial infec- 
tions reported to the Centers for Dis- 
ease Control (CDC) in its National 
Nosocomial Infection Survey (NNIS), 
enterococci were isolated from 11% 
of cases. Frequently, E. faecalis is 
recovered as one of several kinds of 
bacteria causing infections compli- 
cating abdominal or pelvic surgery; in 
such situations, its role is difficult to 
assess. On the other hand, it is 
clearly a pathogen when it is isolated 
from a normally sterile site, such as 
the urinary tract, serous cavities, the 
subarachnoid space, or the blood. 
Enteroccus spp are regarded as a sep- 
arate genus based on DNA homology; 
they are identified in the clinical mi- 
crobiology laboratory by their ability 
to grow in media containing 40% bile, 
cleave esculin, and grow in broth 
containing 6.5% NaCl. Most labora- 
tories do not attempt to speciate en- 
terococci. Enterococci currently 
account for 9% of all nosocomial 
bacteremias that occur at the Univer- 
sity of Michigan Hospital and 14% of 
all bacteremias that occur at the Ann 
Arbor Veterans Administration Hos- 
pital. 
Changes in the Susceptibility of 
Enteroccus faecalis 
Enterococcus fuecalis exemplifies tol- 
erance to antimicrobics. For serious, 
life-threatening infections, e.g., in- 
fective endocarditis, combination 
therapy using an aminocyclitol plus a 
cell-wall active agent is necesary to 
achieve bactericidal therapy. The 
bactericidal action of the combination 
may result primarily from the activity 
of the aminocyclitol; the cell-wall ac- 
tive agent may in some way act 
mainly to facilitate penetration into 
the bacterial cell. Formerly, low- 
level intrinsic resistance to aminocy- 
clitols was the rule in E. faecalis, 
with high-level resistance a rare oc- 
currence. Initially, streptomycin was 
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the aminocyclitol used to treat serious 
infections, usually, in combination 
with penicillin G. Isolates resistant to 
streptomycin were recognized soon 
after it became the treatment of 
choice; fortunately, the newly devel- 
oped aminocyclitols, such as genta- 
micin, were active against all of the 
resistant strains. 
In 1979, the first high-level genta- 
micin resistant E. faecalis were re- 
ported from the Institute Pasteur, and 
in early 1980, the first of such strains 
were reported in the United States. 
Following these reports, screening 
was initiated at several institutions 
leading to the recognition of an in- 
creasing prevalence of these strains as 
causes of nosocomial infections. 
Currently, 13% of E. faecalis isolated 
from normally sterile body sites at the 
University of Michigan Hospital have 
high-level resistance to gentamicin, 
and 55% of all clinical isolates at the 
Ann Arbor Veterans Administration 
Hospital display this phenotype. 
Similarly resistant E. faecalis have 
also been reported from California, 
Illinois, Pennsylvania, Connecticut, 
Washington, and Texas. Serious in- 
fections, including endocarditis, have 
been reported to be caused by isolates 
with high-level resistance. The nature 
of the resistance has varied from in- 
stitution to institution with some iso- 
lates having patterns similar to the 
isolates originally reported from 
France. These isolates are resistant to 
gentamicin and amikacin but remain 
susceptible to streptomycin, pre- 
serving its utility as a therapeutic op- 
tion. Unfortunately, the majority of 
resistant clinical isolates are not in- 
hibited by any of the aminocyclitols. 
In addition to resistance to amino- 
cyclitols, rare isolates also produce 
beta-lactamase. The clinical conse- 
quences are not devastating because 
the beta-lactamase is susceptible to 
inhibition by clavulanic acid. All of 
the beta-lactamase-producing strains 
reported to date have also possessed 
high-level resistance to gentamicin. 
Epidemiology 
Infection with E. faecalis traditionally 
has been considered to be acquired 
from endogenous flora. The sudden 
increase of high-level gentamicin re- 
sistant isolates of E. faecalis in a 
number of institutions prompted re- 
examination of the epidemiology of 
infection caused by enterococci, espe- 
cially as clusters of infection in both 
geography and time were recognized. 
Detailed study of the epidemiology of 
enterococcal infections is limited by 
the lack of a typing system. How- 
ever, by using total plasmid content 
and restriction endonuclease digests of 
plasmid DNA as indicators of strain 
identity, identical organisms were re- 
covered from several groups of pa- 
tients housed on the same nursing 
unit. It seemed unlikely that all of 
the patients carried the same organism 
endogenously and then became in- 
fected from their own flora; exoge- 
nous acquisition seemed more likely. 
Exogenous acquisition of E. faecalis 
was documented subsequently in a 
prospective study in an intensive care 
unit where high-level gentamicin re- 
sistance was endemic. Within the 
limits of detection by culture, patients 
newly admitted to the unit were nega- 
tive; subsequently, while in the unit, 
they acquired resistant enteroeocci. 
Cross-infection was suggested by the 
ease of recovery of high-level resis- 
tant E. faecalis from the hands of 
personnel working in the unit. The 
reservoir and mode of transmission 
are remarkably similar to the multi- 
drug resistant Enterobacteriaceae that 
frequently cause similar problems in 
the hospital environment. 
Mechanisms of Resistance 
The high-level resistance to genta- 
micin in E. faecalis in the original 
isolates described at the Institute Pas- 
teur had resistance genes on a 
plasmid. This has been true in the 
isolates from the United States as 
well. The plasmids have been heter- 
ogeneous, varying in molecular mass, 
restriction patterns, and genes en- 
coding additional resistances. This 
argues against selection of a resistant 
clone with subsequent dissemination 
but rather suggests involvement of 
transposition in the evolution of these 
plasmids. The resistance of several 
isolates from the United States and 
Europe is the result of inactivating 
enzymes and is thus similar to the 
plasmid-mediated resistance found in 
Gram-negative bacilli. Several dif- 
ferent enzymes are produced in the 
most commonly isolated strains. 
The DNA sequence responsible for 
resistance to gentamicin that resides 
on piP800, the plasmid carded by the 
original French isolates, has been 
cloned and sequenced. This sequence 
encodes for a protein that is bifunc- 
tional, having 6'-acetyltransferase 
[AAC (6')] and 2"-phosphotransferase 
[APH (2")] activities. Additional 
adenylating activity found in the 
strains predominant in the United 
States results in inactivation of strep- 
tomycin, rendering all commercially 
available aminocyclitols ineffective. 
Detection 
The prevalence of high-level resis- 
tance to gentamicin in Enterococcus 
spp appears to have increased since it 
was first reported in 1979. Standard 
susceptibility testing, including disk 
diffusion and microtiter MICs, does 
not discriminate between the usual 
moderate level of intrinsic resistance 
and high-level resistance. Although 
the zone size from Kirby-Bauer disk 
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diffusion tests might provide a clue, a 
poor correlation between MIC and 
zone size appears to be the rule with 
resistant Enterococcus spp. A single- 
well microdilution test for screening 
high-level resistance appears to pro- 
vide the most useful information, 
yielding a positive predictive value of 
over 99% and a specificity of 100%. 
This test is similar to the single tube 
screening test devised for detecting 
resistance to streptomycin; instead of 
2000 ug/ml of streptomycin, 500 
ug/mi of gentamicin is used. The test 
provides a yes or no screen; growth 
correlates with lack of aminocyclitol- 
penicillin synergy. Screening with 
the single tube test appears to be 
useful for blood and other normally 
sterile body-fluid isolates; testing 
gentamicin alone is sufficient for ini- 
tial screening. If the isolates display 
high-level resistance to gentamicin, 
additional testing using the single tube 
test for streptomycin at 2000 ug/ml is 
useful because occasional isolates are 
Table 1. Susceptibility of Enterococcus 
faecalie UM 2906 
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susceptible to streptomycin but resis- 
tant to gentamicin. 
Therapy 
The clinical infections caused by re- 
sistant Enterococcus spp mirror the 
spectrum of infections caused by or- 
dinary E. faecalis. The approach to 
therapy for urinary tract infections, 
soft-tissue infection, and mixed infec- 
tions that can be drained surgically is 
no different than for routine isolates. 
Inhibitory therapy with cell-wall ac- 
tive agents seems to be adequate. 
Endocarditis and bacteremia compli- 
cating nondebrideable foci, such as 
extensive bums or mediastinitis, are 
major therapeutic problems. With 
isolates apparently susceptible to 
streptomycin, using the 2000 ug/ml 
screen, streptomycin may be com- 
bined with penicillin or vancomycin. 
Formal synergy studies should be car- 
ried out with isolates causing serious 
infections in order to document the 
activity of streptomycin. If no amin- 
ocyclitol is active, bactericidal therapy 
cannot be delivered. Search for a re- 
placement for the aminocyclitol com- 
ponent of the traditional combination 
regimens has not been fruitful so far. 
High-dose ampicillin has been sug- 
gested as one approach; usually, there 
is clearance of bacteremia with im- 
provement in clinical parameters of 
infection, followed by relapse when 
therapy is stopped. A few patients do 
respond and are apparently cured; 
success has been reported with van- 
comycin as well. These successes 
may represent infections caused by 
strains of E. faecalis that are killed 
rapidly by cell-wall active agents 
alone. However, a regimen that is 
consistently bactericidal against amin- 
ocyclitol-resistant E. faecalis is 
needed to control serious infections 
caused by these emerging pathogens. 
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